Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop it in its tracks.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus nephritis is treated in children, writes Neha Gupta for Insider Monkey. Late ...

This announcement makes the Benlysta autoinjector the first subcutaneous treatment option available for pediatric patients with LN, a serious complication of lupus.

A 43-year-old man presents requesting screening for sexually transmitted infections (STIs). His medical history is remarkable for systemic lupus erythematosus (SLE), and he is currently receiving no ...

Diffuse Large B-Cell Lymphoma Pipeline constitutes 70+ key companies continuously working towards developing 75+ Diffuse Large B-Cell Lymphoma treatment therapies, analyzes DelveInsight.

Google's new multi-vector retrieval algorithm (MUVERA) improves search speed and performs better on complex queries.